1	Diagnostic Accuracy of the Abbot BinaxNOW COVID-19 Antigen Card Test, Puerto Rico						
2							
3	Zachary J. Madewell ¹ , Chelsea G. Major ¹ , Nathan Graff ² , Cameron Adams ³ , Dania M. Rodriguez ¹ ,						
4	Tatiana Morales ⁴ , Nicole A. Medina Lopes ¹ , Rafael Tosado ¹ , Liliana Sánchez-González ¹ , Janice Perez-						
5	Padilla ¹ , Hannah R. Volkman ¹ , Jorge Bertran ⁵ , Diego Sainz ⁵ , Jorge Munoz-Jordan ¹ , Gilberto A.						
6	Santiago ¹ , Olga Lorenzi ¹ , Vanessa Rivera-Amill ⁴ , Melissa A. Rolfes ⁶ , Gabriela Paz-Bailey ¹ , Laura E.						
7	Adams ¹ , Joshua M. Wong ¹ , PRESCA Study Team						
8							
9	Affiliations						
10	1. Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, Puerto						
11	Rico						
12	2. Eagle Health Analytics, San Antonio, Texas, USA						
13	3. Department of Microbiology and Immunology, University of North Carolina School of Medicine,						
14	Chapel Hill, North Carolina, USA						
15	4. Ponce Health Sciences University/Ponce Research Institute, Ponce, Puerto Rico						
16	5. Auxilio Mutuo Hospital, San Juan, Puerto Rico						
17	6. Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA						
18							
19	Corresponding author: Zachary J. Madewell						
20	Corresponding author email: <u>ock0@cdc.gov</u>						
21							
22	Running title: Abbot BinaxNOW COVID-19 Antigen Card test						
23	Data availability: Due to data security and confidentiality guidelines, all analyses, and restricted-use						
24	datasets, including questionnaire forms and code, must be requested from CDC and PMFS after						
25	submitting a concept proposal to <u>dengue@cdc.gov</u> .						
26	Funding: This work was supported by the National Center for Emerging and Zoonotic Infectious						
27	Diseases and the Center for State, Tribal, Local, and Territorial Support at the Centers for Disease Control						
28	and Prevention [grant numbers U01CK000437 and U01CK000580 to V.R.A.]. The funders had no role in						
29	study design, data collection and analysis, decision to publish, or preparation of the manuscript.						
3U 21	https://www.cdc.gov/ncezid/index. html https://www.cdc.gov/publichealthgateway/about-						
J⊥ DD	<u>CSUIS/INDEX.NUMI</u> .						
3Z	Conflict of interest: The authors declare no conflict of interests.						

- 33 Ethics approval and consent to participate: Approval for the COPA project was obtained from the
- 34 Ponce Medical School Foundation, Inc. Institutional Review Board (protocol number 171110-VR). The
- 35 Institutional Review Boards at the CDC, Auxilio Mutuo, and Ponce Medical School Foundation approved
- 36 the SEDSS study protocols 6214, and 120308-VR, respectively. Written consent to participate was
- 37 obtained from all adult participants and emancipated minors; parental written consent and participant
- 38 assent were obtained for children.

- 39 **Disclaimer**: The findings and conclusions in this report are those of the authors and do not necessarily
- 40 represent the official position of the US Centers for Disease Control and Prevention.

41 Abstract

42	Background: The COVID-19 pandemic underscored the need for rapid and accurate diagnostic tools. In
43	August 2020, the Abbot BinaxNOW COVID-19 Antigen Card test became available as a timely and
44	affordable alternative for SARS-CoV-2 molecular testing, but its performance may vary due to factors
45	including timing and symptomatology. This study evaluates BinaxNOW diagnostic performance in
46	diverse epidemiological contexts.
47	Methods: Using RT-PCR as reference, we assessed performance of the BinaxNOW COVID-19 test for
48	SARS-CoV-2 detection in anterior nasal swabs from participants of two studies in Puerto Rico from
49	December 2020 to May 2023. Test performance was assessed by days post symptom onset, collection
50	strategy, vaccination status, symptomatology, repeated testing, and RT-PCR cycle threshold (Ct) values.
51	Results: BinaxNOW demonstrated an overall sensitivity of 84.1% and specificity of 98.8%. Sensitivity
52	peaked within 1–6 days after symptom onset (93.2%) and was higher for symptomatic (86.3%) than
53	asymptomatic (67.3%) participants. Sensitivity declined over the course of infection, dropping from
54	96.3% in the initial test to 48.4% in testing performed 7–14 days later. BinaxNOW showed 99.5%
55	sensitivity in participants with low Ct values (\leq 25) but lower sensitivity (18.2%) for participants with
56	higher Cts (36–40).
57	Conclusions: BinaxNOW demonstrated high sensitivity and specificity, particularly in early-stage
58	infections and symptomatic participants. In situations where test sensitivity is crucial for clinical decision-
59	making, nucleic acid amplification tests are preferred. These findings highlight the importance of
60	considering clinical and epidemiological context when interpreting test results and emphasize the need for
61	ongoing research to adapt testing strategies to emerging SARS-CoV-2 variants.
62	

63 Keywords: Rapid Antigen Test; Omicron; Diagnostic Accuracy; Puerto Rico; Sensitivity; SARS-CoV-2

64 Introduction

As of October 2023, the COVID-19 pandemic has led to 771 million confirmed cases of COVID-65 66 19 and 7 million deaths globally, with Puerto Rico reporting almost 1.3 million COVID-19 cases and 67 6,000 associated deaths.¹ Rapid identification of SARS-CoV-2 infection and subsequent measures to reduce transmission are central to an effective public health response to COVID-19.² However, the broad 68 69 spectrum of clinical manifestations of SARS-CoV-2 infection poses a challenge to the rapid identification of infections and the implementation of effective measures to reduce transmission.²⁻⁴ Concurrently, the 70 pandemic prompted the development of novel therapies ⁵⁻⁸ that are designed to shorten COVID-19 71 72 symptom duration. Early identification of SARS-CoV-2 infection is crucial for the timely and appropriate 73 administration of therapies, particularly for people at higher risk for severe disease. Many of the novel 74 treatments developed during the pandemic require initiation within a specific window after symptom 75 onset. However, the challenges posed by the broad spectrum of clinical manifestations, including initially 76 asymptomatic and mild cases that can progress to severe disease, make early and accurate detection of 77 SARS-CoV-2 infection essential for effective treatment and prevention strategies. 78 To identify infected individuals for isolation and appropriate medical therapy, rapid and accurate 79 COVID-19 tests continue to play a crucial role, including those used in clinical and laboratory settings. 80 Although RT-PCR-based testing is frequently available in clinical and laboratory settings for infection 81 detection, its utility can be limited by the expertise required for proper sample management and reporting delays due to the time needed for transport and testing at laboratory facilities.^{9,10} In many communities, 82 83 point-of-care rapid antigen tests were deployed to enhance the accessibility and efficiency of SARS-CoV-84 2 infection detection. Among the available commercial lateral flow antigen tests, the BinaxNOW Antigen 85 Card test has undergone particularly extensive evaluation, demonstrating consistent specificity (>97%) across multiple cohort studies.¹¹⁻¹⁵ However, sensitivity estimates varied widely in different reports, with 86 87 potential factors including timing of specimen collection, symptom presence, collection methodology, and 88 viral replication levels, necessitating further validation.

89	In December 2020, BinaxNOW testing was introduced alongside RT-PCR testing for SARS-
90	CoV-2 in a community cohort and two clinical surveillance sites in Puerto Rico. We evaluated how the
91	performance of BinaxNOW varied by days post onset of symptoms, symptomatology, predominant
92	SARS-CoV-2 variant, vaccination status, collection strategy, repeated tests, and RT-PCR cycle thresholds
93	(Ct). This study leverages its large sample size, including specimens collected at various time points from
94	a unique population in Puerto Rico, to provide a comprehensive evaluation of the BinaxNOW Antigen
95	Card test's performance, contributing to filling an information gap in the use of point-of-care rapid
96	antigen tests for SARS-CoV-2 infection detection. Our findings contribute to a deeper understanding of
97	the test's efficacy and role in augmenting current diagnostic strategies.
98	
99	Methods
100	Study Design and Data Collection
101	The data analyzed is derived from two observational studies in Puerto Rico: the Communities
102	Organized to Prevent Arboviruses (COPA) study and the Sentinel Enhanced Dengue Surveillance System
103	(SEDSS), both of which are conducted by the Ponce Health Sciences University (PHSU) and the US
104	Centers for Disease Control and Prevention's (CDC) Dengue Branch (DB).
105	COPA is a community-based cohort study established in Ponce, Puerto Rico, in 2018. Study
106	enrollment and data collection activities are described elsewhere. ¹⁶⁻¹⁸ Briefly, study activities include
107	annual interviews and serum collection for arbovirus testing among approximately 3,800 participants.
108	Beginning in April 2020, anterior nasal swabs for SARS-CoV-2 RT-PCR testing were collected from
109	participants that reported experiencing COVID-like symptoms (i.e., fever, cough, sore throat, difficulty
110	breathing, diarrhea, body pain, or loss of taste/smell) or within the last 7 days of their annual visits.
111	Additionally, an acute illness surveillance component was initiated via weekly text messages asking
112	participants to report if they or a household member experienced COVID-like symptoms in the past 7
113	days. Symptomatic participants, as well as those with a prior positive lab test for SARS-CoV-2 in the last
114	7-21 days and their household contacts, were offered visits for anterior nasal swab collection for SARS-

115 CoV-2 RT-PCR testing. Beginning in December 2020, concurrent collection of a second anterior nasal 116 swab for testing by the BinaxNOW COVID-19 Antigen Card test was offered to all participants with a 117 swab collected for SARS-CoV-2 RT-PCR testing. All nasal swabs were collected by study staff, and 118 BinaxNOW testing was performed within one hour of collection at the study site. Our analyses include 119 COPA participants who were tested for SARS-CoV-2 between December 2020 and May 2023 using both 120 BinaxNOW and RT-PCR assays. COPA participants may have been tested multiple times in the study 121 period, including during the same and separate illness or exposure events. 122 Established in May 2012, SEDSS is an active surveillance system that monitors acute febrile and 123 respiratory illnesses in two emergency departments in Ponce, Puerto Rico. In 2018, an additional site was established in an emergency department in San Juan.²¹⁻²³ Patients were eligible for enrollment if they 124 125 demonstrated fever upon presentation or within the past week (oral temperature \geq 38°C, axillary 126 temperature \geq 38.5°C), or cough/dyspnea within the last 14 days (with or without fever). Nasopharyngeal 127 swabs collected at enrollment from participants in SEDSS were tested for SARS-CoV-2 using RT-PCR. 128 Two collection approaches were employed for BinaxNOW testing in one of the two participating 129 emergency departments: staff-collected and participant-collected (self-testing) anterior nasal swabs. 130 Participants underwent staff-collected, self-collected, or both staff- and self-collected anterior nasal 131 swabbing concurrently. Participants were provided with clear and simple instructions for self-collection 132 and testing, including applying drops to the test card, swabbing both nostrils, and following specific steps for test card handling.²⁵ Our analyses included SEDSS participants in the San Juan or Ponce sites tested 133 134 for SARS-CoV-2 between January and April 2021 using both BinaxNOW and RT-PCR assays. 135 For both COPA and SEDSS, the RT-PCR assays used included the CDC Real-Time Reverse 136 Transcription PCR Panel for tests performed before December 2021 and the CDC Influenza SARS-CoV-137 2 (Flu SC2) Multiplex Assay for tests performed December 2021 and later.^{19,20} 138

139 Statistical Analysis

140 We reported frequencies of demographic characteristics (age group, sex, ethnicity, race, and Hispanic/Latino), reported chronic medical conditions, COVID-19 vaccine doses, and number of RT-141 142 PCR/BinaxNOW tests among all COPA and SEDSS participants with one or more RT-PCR/BinaxNOW 143 test result data available. 144 Using the SARS-CoV-2 RT-PCR result as our reference standard, we calculated measures of 145 diagnostic accuracy of BinaxNOW tests including sensitivity, specificity, positive predictive value, 146 negative predictive value, positive likelihood ratio, negative likelihood ratio, and the number needed to 147 diagnose (NND) of BinaxNOW tests compared to RT-PCR tests. Definitions of these measures are given 148 in Table S1. We calculated 95% confidence intervals (CI) for all measures. We used McNemar's test to 149 evaluate differences in proportions of discordant pairs (i.e., the differences between false positives and false negatives) between BinaxNOW and the reference standard, RT-PCR.²⁶ It helps determine if one test 150 151 is more likely to produce false positives or false negatives compared to the other. To assess 152 discrimination, we calculated the area under the receiver operating characteristic curve (AUC-ROC). 153 AUC-ROC summarizes the trade-off between sensitivity and specificity, where an AUC of 1 indicates 154 perfect discrimination, and 0.5 indicates no discrimination. 155 We evaluated the performance of BinaxNOW compared to RT-PCR overall across all participants 156 as well as by days post symptom onset (0, 1-3, 4-6, 7+ days), symptom status (asymptomatic, 157 symptomatic), collection strategy (staff-collected, self-collected), number of COVID-19 vaccine doses 158 received prior to testing (0, 1, 2, 3 doses), primary SARS-CoV-2 variant (pre-Delta, Delta, Omicron) 159 circulating at time of sample collection, and Ct values of positive RT-PCR tests ($\leq 25, 26-30, 31-35, 36-$ 160 40). The classification of primary circulating SARS-CoV-2 variant was based on the time period from 161 their earliest detection in Puerto Rico until the detection of a new major variant: pre-Delta (cases through 162 May 31, 2021), Delta (June 1 to November 30, 2021), and Omicron (after December 1, 2021).²⁷ 163 For COPA participants with repeated tests, we evaluated BinaxNOW performance for their initial 164 test as well as the repeated test 7–14 days after the initial test. We further stratified this analysis by 165 participant symptom status for the initial and repeated tests. We performed a sensitivity analysis for the

166	repeated tests by restricting to participants who had testing within 6 days of symptom onset to ensure the
167	repeated test was not for a different infection. For repeated tests among COPA participants, tests
168	separated by ≥ 90 days were considered as part of separate illness episodes, and tests within 7–14 days of
169	each other were considered part of the same illness episode. ²⁸ The few COPA participant tests performed
170	between 15–89 days of another test were excluded from the analysis. In SEDSS, when both self-collected
171	and hospital staff-collected swabs were tested, all tests, including the RT-PCR test, were conducted on the
172	same day and included in the analyses.
173	We fit cubic splines to further understand the relationships between sensitivity and specificity of
174	BinaxNOW by days post onset of symptoms and total number of symptoms. All analyses were done using
175	R software, version 4.3.1 (R Foundation for Statistical Computing, Vienna, Austria).
176	
177	Results
178	There were 1,207 total participants with results from paired BinaxNOW and RT-PCR tests: 943
179	(78.1%) from COPA and 264 (21.9%) from SEDSS (Table 1). The median age of all participants was 36
180	years (IQR: 17, 49), 57.4% were female, 99.7% were Hispanic/Latino, and 56.3% had reported past
181	diagnosis with one or more chronic medical conditions. Of 799 COPA participants with available
182	COVID-19 vaccine data, 92.5% had received at least two doses, whereas 5.8% remained unvaccinated.
183	All SEDSS participants were unvaccinated and tested before vaccines became widely available in Puerto
184	Rico. Among the 264 SEDSS participants, 58 (22.0%) underwent both staff-collected/tested and
185	participant-collected/tested BinaxNOW tests, resulting in a total of 322 BinaxNOW tests. In COPA, there
186	were 1,208 BinaxNOW tests from the 943 participants from December 2020 to May 2023. Of the 1,530
187	total tests from SEDSS and COPA, 404 (26.4%) were positive for SARS-CoV-2 on the BinaxNOW test
188	and 465 (30.4%) were positive by RT-PCR.
189	Across all participants (n=1,530 paired tests), the overall sensitivity of BinaxNOW compared to
190	RT-PCR was 84.1% (95% CI: 80.4%-87.3%), specificity was 98.8% (95% CI: 97.9%-99.3%), positive
191	predictive value was 96.8% (95% CI: 94.6%–98.3%), and negative predictive value was 93.4% (95% CI:

192 91.8%–94.8%) (Table 2). We further examined the diagnostic performance at different time intervals 193 following symptom onset. Sensitivities at 1-3 days post onset (92.1%) and 4-6 days post onset (94.2%) 194 were significantly higher than at >7 days post onset (70.2%) (p<0.001). Specificity remained consistently 195 above 98% across all days post-onset. The sensitivity of the BinaxNOW test peaked between 1 and 6 days 196 post-onset and waned thereafter (Figure 1). 197 The sensitivity of BinaxNOW was higher for symptomatic (86.3%) than for asymptomatic 198 (67.3%) participants, whereas specificity estimates were the same (98.8%) for both groups. Sensitivity did 199 not significantly vary by the number of symptoms reported (Figure S1). For symptomatic participants, 200 one correct diagnosis was obtained for every 1.2 patients tested with BinaxNOW on average during the 201 study period (NND = 1.2,95% CI: 1.1-1.2) (Table 3). For asymptomatic participants, one correct 202 diagnosis was obtained for every 1.5 patients tested with BinaxNOW on average during the study period 203 (NND = 1.5, 95% CI: 1.3-2.0). The sensitivity and specificity of BinaxNOW showed consistent 204 performance across participants regardless of the number of COVID-19 vaccine doses received, with 205 overlapping confidence intervals for all groups (Table 2). 206 We evaluated the diagnostic performance of BinaxNOW using swabs collected and tested by 207 participants, as well as those collected and tested by study staff. BinaxNOW testing of self-collected and 208 staff-collected anterior nasal swabs from SEDSS showed sensitivities of 85.2% and 79.3%, respectively, 209 and 100% specificity (Table 2). BinaxNOW testing of staff-collected anterior nasal swabs from COPA 210 had 84.3% sensitivity and 98.4% specificity. BinaxNOW tests in anterior nasal swabs collected by both 211 participants (AUC-ROC = 0.926) and staff (AUC-ROC = 0.913) showed a strong ability to discriminate 212 between true positives and true negatives (Table 3). Among individuals positive by RT-PCR, SEDSS 213 participants had lower median Ct values (23, IQR: 21-30) compared to symptomatic COPA participants 214 (27, IQR: 23-31) (p=0.004) and a higher median number of symptoms (9, IQR: 5-12) compared to 215 symptomatic COPA participants (1, IQR: 1-1) (p<0.001). In the COPA cohort, sensitivity was 55.4% 216 (95% CI: 44.1%–66.3%) for 83 positive RT-PCR tests from asymptomatic participants and 86.8% (95%

217 CI: 82.8%–90.1%) for 355 positive RT-PCRs from symptomatic participants (Figure S2).

218	There were 184 participants who had repeated tests within a single illness or exposure event (7-
219	14 days after the initial test). In the initial test, BinaxNOW demonstrated high sensitivity (96.3%) and
220	specificity (96.0%) for detecting SARS-CoV-2 (Table 2). During subsequent sample collection and
221	testing 7–14 days later, sensitivity decreased to 48.4%, while specificity remained high at 97.9% (p-value
222	from McNemar's test < 0.001). Restricting to 134 participants who had the initial test within 6 days of
223	symptom onset, the sensitivity was 96.1% for the initial test and 48.8% for the repeated test 7-14 days
224	later. The initial test showed strong overall performance (AUC-ROC = 0.961), whereas the follow-up
225	testing showed a decline in accuracy for identifying positive cases over time (AUC-ROC = 0.731) (Table
226	3). Sensitivity dropped significantly for participants initially symptomatic (98.7%) and later
227	asymptomatic (23.1%) (Figure 2, Table S2). Conversely, sensitivity increased for those initially
228	asymptomatic (50.0%) and later symptomatic (100%), but this difference was not statistically significant
229	possibly due to the limited sample size.
230	The sensitivity of BinaxNOW varied significantly depending on the Ct values from positive RT-
231	PCR tests. For Ct values ≤25, paired BinaxNOW tests showed 99.5% sensitivity in correctly identifying
232	positive cases (Table 4). Conversely, as Ct values increased, test accuracy declined, reaching only 18.2%
233	for Ct values between 36–40.
234	
235	Discussion
236	Our results demonstrated an overall 84.1% sensitivity for the Abbot BinaxNOW COVID-19
237	Antigen Card Test which falls within the upper range of previously reported BinaxNOW sensitivities
238	(50–85%) among other studies. ^{11-14,29} The test also demonstrated high specificity (98.8%), positive
239	predictive value (96.8%), and negative predictive value (93.4%). Test sensitivity was highest 1-6 days
240	post onset and decreased significantly thereafter. These findings are in agreement with other studies,
241	highlighting the importance of timing in SARS-CoV-2 antigen testing. ^{30,31}
242	Our findings regarding BinaxNOW test performance in symptomatic and asymptomatic
243	individuals also align with those from other studies, ¹¹⁻¹⁴ showing substantially higher test sensitivity in

244 symptomatic compared to asymptomatic individuals, while maintaining a high level of specificity for 245 both groups. We did not find a clear dose-response relationship between the number of symptoms 246 experienced and sensitivity, but the point estimate for test sensitivity was highest (91.5%) among 247 participants with ten or more symptoms. Symptom type and indicators of disease severity, such as low 248 oxygen saturation levels, tachypnea, or requiring hospitalization, rather than simply the number of symptoms reported, may have a greater influence on diagnostic accuracy.³² These results corroborate 249 250 previous research and highlight the challenges of detecting SARS-CoV-2 infections in asymptomatic 251 cases.¹¹⁻¹⁴ Clinicians should consider these factors and follow CDC guidelines for using antigen tests, 252 including repeat testing for asymptomatic individuals who were exposed, considering other etiologies for 253 symptomatic individuals, and repeating testing with RT-PCR in situations where sensitivity is of 254 paramount importance according to CDC recommendations.³³

255 Following infection, SARS-CoV-2 viral replication and shedding precede symptoms, with peak 256 viral titers occurring near the day of symptom onset and declining thereafter.³⁴ This trend is supported by 257 studies indicating that antigen testing demonstrates higher sensitivity early in infection when viral loads are high, while repeated sampling over the illness course correlates with decreasing sensitivity.^{11,30,31,35,36} 258 259 Ct values from RT-PCR tests also provide quantity of viral genetic material in the sample (as an 260 approximate proxy for viral load) with increasing Ct values reflecting decreasing viral genetic 261 material.³⁷³⁸ Our study used the same RT-PCR assay for SEDSS participants, but two different RT-PCR 262 assays were used in COPA, which precludes direct comparison of Ct values due to variation in sensitivity, chemistry of reagents, gene targets, cycle parameters, and others.³⁷ BinaxNOW test showed peak 263 264 sensitivity (99.5%) when the Ct values of paired RT-PCR tests were 25 or lower, suggesting a higher 265 concentration of viral genetic material, typically indicative of early-stage infection. This is consistent with 266 our findings of reduced sensitivity 7 or more days after symptom onset, as well as those showing a 267 significant decline in sensitivity with repeated testing conducted in samples collected 7-14 days after 268 initial testing. These findings emphasize the importance of testing during the early infection stage and 269 maximizing the utility of isolation and treatment, when indicated. However, BinaxNOW test sensitivity

drops significantly (18.2%) for cases with Ct values between 36–40, suggesting a diminished capacity to
detect positive SARS-CoV-2 cases among individuals with lower viral genetic material concentrations
during later stages of infection.

273 Compared to ancestral variants, Delta and Omicron are characterized by their shorter incubation periods, serial intervals, enhanced immune evasion, and heightened transmissibility.³⁹⁻⁴¹ Studies have 274 275 yielded mixed results in viral load patterns for these variants, with some reporting higher viral loads for 276 Delta,^{42,43} whereas others report higher viral loads for Omicron BA.1.^{44,45} The limited number of tests 277 during the Delta variant dominant period in our study precluded robust comparisons of sensitivity 278 between SARS-CoV-2 variants, and there were overlapping confidence intervals for sensitivity across the 279 variants. One study reported lower BinaxNOW COVID-19 Antigen test sensitivity for infections with the Omicron variant compared to those with the Delta variant,⁴⁶ and another found no significant difference 280 in sensitivity between the two variants.⁴⁷ The impact of infection prevalence, such as the lower prevalence 281 282 in the Delta period, may have affected the results. Lower prevalence can lead to higher false-negative 283 rates as the proportion of true negatives in the population increases, influencing the balance of sensitivity 284 and specificity. Sensitivity and specificity of the BinaxNOW test remained consistent across participants 285 regardless of their COVID-19 vaccination status, similar to other studies.^{29,48}

Test timing, the patient's clinical presentation, and the prevalence of SARS-CoV-2 infection in the community should be considered when interpreting results and making diagnostic decisions. This approach aligns with CDC guidance on COVID-19 testing.⁴⁹ Different settings require tailored testing strategies. Healthcare settings attending to immunocompromised individuals may rely on highly sensitive RT-PCR tests to accurately detect prolonged viral shedding. Conversely, antigen tests may provide sufficient diagnostic accuracy in most settings, particularly when timely results are essential for public health intervention or treatment.

Our study evaluated the performance of BinaxNOW COVID-19 Antigen test for both selfcollected and staff-collected anterior nasal swab samples. We observed high sensitivities (85.2% and
83.9%) and specificities (>98%) for both collection methods, consistent with the literature emphasizing

the feasibility and reliability of self-collection methods.^{50,51} Sensitivity among participants from the 296 297 hospital-based surveillance site (SEDSS) (83.1%) was not significantly different than among 298 symptomatic participants from the community-based cohort (COPA) (86.8%), but was significantly 299 higher than asymptomatic COPA participants (55.4%). 300 This study had several limitations. Our population was composed primarily of individuals that 301 identified as Hispanic/Latino and Puerto Rican between the ages of 0 and 50 years, which may not fully 302 represent diverse populations or epidemiological conditions found elsewhere. BinaxNOW performance 303 may vary in populations with different demographic characteristics, vaccination rates, or healthcare 304 access. Additionally, participants in our study, comprising individuals seeking medical attention or 305 enrolling in a community-based cohort study, may differ from non-participants regarding healthcare-306 seeking behavior, symptom severity, proximity to healthcare facilities, access to healthcare, 307 socioeconomic factors, and risk perception, potentially introducing selection bias. Our study included pre-308 Delta, Delta, and Omicron (time period covering BA.1 through XBB.1.5⁵²) variants. However, our study 309 population had low SARS-CoV-2 transmission prior to the Omicron variant. More recent Omicron 310 subvariants like EG.5 and FL.1.5.1 may have viral mutations that affect BinaxNOW performance. 311 Furthermore, our study used the dominant variant period as a proxy for the actual variant of the 312 individual, potentially misclassifying cases due to variability within these periods. Lastly, our study 313 focused on a rapid antigen test for SARS-CoV-2 from a single manufacturer. Our findings may not apply 314 to other antigen tests with potentially different performance characteristics. 315

316 Conclusions

Our study provides valuable insights into the diagnostic performance of BinaxNOW COVID-19
Antigen Card Test in different epidemiological contexts. While demonstrating high sensitivity and
specificity, our findings highlight the influence of factors such as symptomatology, viral load, and timing
of specimen collection on test accuracy. BinaxNOW remains a valuable tool for home use and early
infection identification, offering numerous advantages, including low cost, extended shelf life,

- 322 temperature stability, ease of use, and the ability to identify individuals with high viral loads. However,
- 323 its application should be considered alongside clinical and epidemiological context.³³ Future research
- 324 should continue to explore the evolving landscape of SARS-CoV-2 variants and the performance of rapid
- antigen tests across diverse populations to further enhance our understanding and response to COVID-19.
- 326

327 **References**

- World Health Organization. WHO Coronavirus (COVID-19) Dashboard. October 12, 2023.
 Accessed October 12, 2023. <u>https://covid19.who.int/</u>
- 2. Centers for Disease Control and Prevention. Isolation and Precautions for People with COVID 19. October 3, 2023. Accessed October 3, 2023. <u>https://www.cdc.gov/coronavirus/2019-</u>
 <u>ncov/your-health/isolation.html</u>
- 333 3. Sah P, Fitzpatrick MC, Zimmer CF, et al. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. *Proc Natl Acad Sci U S A*. Aug 24
 2021 110(24) 1 : 10 1072/ 201110
- 335 2021;118(34)doi:10.1073/pnas.2109229118
- Wong JM, Volkman HR, Adams LE, et al. Clinical Features of COVID-19, Dengue, and
 Influenza among Adults Presenting to Emergency Departments and Urgent Care Clinics-Puerto
 Rico, 2012-2021. *Am J Trop Med Hyg.* Jan 11 2023;108(1):107-114. doi:10.4269/ajtmh.22-0149
- Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. *N Engl J Med.* Jan 7 2021;384(1):20-30. doi:10.1056/NEJMoa2030340
- 341 6. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk,
 342 Nonhospitalized Adults with Covid-19. *N Engl J Med.* Apr 14 2022;386(15):1397-1408.
 343 doi:10.1056/NEJMoa2118542
- Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of
 Covid-19 in Nonhospitalized Patients. *N Engl J Med*. Feb 10 2022;386(6):509-520.
 doi:10.1056/NEJMoa2116044
- 8. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 Final
 Report. *N Engl J Med.* Nov 5 2020;383(19):1813-1826. doi:10.1056/NEJMoa2007764
- 349 9. Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized
 350 patients clinically diagnosed with COVID-19. *J Med Virol*. Jul 2020;92(7):903-908.
 351 doi:10.1002/jmv.25786
- 352 10. Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based tests for
 353 diagnosis of SARS-CoV-2 infection. *Cochrane Database Syst Rev.* Mar 24 2021;3(3):Cd013705.
 354 doi:10.1002/14651858.CD013705.pub2
- Prince-Guerra JL, Almendares O, Nolen LD, et al. Evaluation of Abbott BinaxNOW Rapid
 Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites Pima County,
 Arizona, November 3-17, 2020. *MMWR Morb Mortal Wkly Rep.* Jan 22 2021;70(3):100-105.
 doi:10.15585/mmwr.mm7003e3
- 359 12. Siddiqui ZK, Chaudhary M, Robinson ML, et al. Implementation and Accuracy of BinaxNOW
 360 Rapid Antigen COVID-19 Test in Asymptomatic and Symptomatic Populations in a High361 Volume Self-Referred Testing Site. *Microbiol Spectr.* Dec 22 2021;9(3):e0100821.
 362 doi:10.1128/Spectrum.01008-21
- Almendares O, Prince-Guerra JL, Nolen LD, et al. Performance Characteristics of the Abbott
 BinaxNOW SARS-CoV-2 Antigen Test in Comparison to Real-Time Reverse Transcriptase PCR
 and Viral Culture in Community Testing Sites during November 2020. *J Clin Microbiol.* Jan 19
 2022;60(1):e0174221. doi:10.1128/JCM.01742-21

367	14.	Sood N, Shetgiri R, Rodriguez A, et al. Evaluation of the Abbott BinaxNOW rapid antigen test
368		for SARS-CoV-2 infection in children: Implications for screening in a school setting. <i>PLoS One</i> .
369		2021;16(4):e0249710. doi:10.1371/journal.pone.0249710
370	15.	Pilarowski G, Marquez C, Rubio L, et al. Field Performance and Public Health Response Using
371		the BinaxNOWTM Rapid Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
372		Antigen Detection Assay During Community-Based Testing. Clin Infect Dis. Nov 2
373		2021;73(9):e3098-e3101. doi:10.1093/cid/ciaa1890
374	16.	Adams LE, Sánchez-González L, Rodriguez DM, et al. Risk factors for infection with
375		chikungunya and Zika viruses in southern Puerto Rico: A community-based cross-sectional
376		seroprevalence survey. <i>PLoS Negl Trop Dis</i> . Jun 2022:16(6):e0010416.
377		doi:10.1371/iournal.pntd.0010416
378	17.	Rodríguez DM, Rvff K, Sánchez-Gonzalez L, Rivera-Amill V, Paz-Bailev G, Adams L, HTrack:
379		A new tool to facilitate public health field visits and electronic data capture. <i>PLoS One</i> .
380		2020:15(12):e0244028_doi:10.1371/journal.pone.0244028
381	18	Sánchez-González L. Adams LE. Saavedra R. et al. Assessment of community support for
382	10.	Wolbachia-mediated population suppression as a control method for Aedes acounti mosquitoes in
383		a community cohort in Puerto Rico. <i>PLoS Neal Tran Dis</i> Dec 2021:15(12):e0009966
384		doi:10.1371/journal.pntd.0009966
285	10	Lu X Wang L Sakthivel SK et al. US CDC Real-Time Reverse Transcription PCR Panel for
386	17.	Detection of Severe Acute Respiratory Syndrome Coronavirus 2 <i>Emerg Infact Dis</i> Aug
387		2020.26(8):1654_65_doi:10.3201/eid2608.201246
388	20	Centers for Disease Control and Prevention CDC's Influenza SARS-CoV-2 Multipley Assay
389	20.	November 9, 2023 Accessed November 9, 2023 https://www.cdc.gov/coronavirus/2019-
300		ncov/lab/multipley.html
201	21	Tomashek KM Lorenzi OD Andújar Párez DA et al Clinical and enidemiologic characteristics
302	21.	of dengue and other etiologic agents among natients with acute febrile illness. Puerto Rico, 2012
393		2015 PL oS neglected tronical diseases 2017:11(9):e0005859
394	22	Tomashek KM Rivera A Torres-Velasquez B et al Enhanced Surveillance for Eatal Dengue-
395	22.	Like Acute Febrile Illness in Puerto Rico. 2010-2012, PLoS Neal Tron Dis Oct
396		2016:10(10):e0005025_doi:10.1371/journal.pntd.0005025
397	23	Departamento de Salud Puerto Rico, Orden Administrativa Núm 2021-496 September 26 2023
208	23.	Accessed September 26, 2023, https://www.salud.pr.gov/CMS/DOWNLOAD/3636
200	24	ThermoEisher Scientific TagPathTM 1-Step RT-aPCR Master Mix CG November 8, 2023
400	27.	Accessed November 8, 2023, https://www.thermofisher.com/order/catalog/product/A15200
400	25	Abbott BinayNOW COVID 19 Antigen Test October 12 2023 Accessed October 12 2023
401	23.	https://www.globalpointofeare.abbott/us/en/product.details/binavnow_covid_10_antigen_salf_test
402		https://www.grobalpointoreare.aboot//us/en/product-uctans/oinaxnow-covid-12-antigen-sen-test-
403	26	$\frac{\text{us.ntm}}{\text{McNemar}}$ O Note on the sampling error of the difference between correlated proportions or
404	20.	percentages Psychometrika 1947:12(2):153-157
405	27	Santiago GA, Volkman HP, Elores B, et al. SAPS CoV 2 Omicron Replacement of Delta as
400	27.	Predominant Variant Puerto Pico. Emarging Infactious Disagrees 2023:20(1):855
407	28	Centers for Disease Control and Prevention Investigative Criteria for Suspected Cases of SARS
100	20.	CoV 2 Painfaction (ICR) Sentember & 2023 Accessed Sentember & 2023
405 //10		https://stacks.cdc.gov/view/cdc/06072
410	20	Schrom I. Marguaz C. Poterson M. DaPici I. Haylir D. Comparison of SAPS CoV 2 Poverso
411	29.	Transprintese Delymorese Chain Desetion and DineyNOW Denid Antigen Tests at a Community
412 //12		Site During an Omicron Surge Ann Intern Med Oct 2022;175(10):W110 doi:10.7226/122.0257
413 /1/	20	Abusrowil 7 Albudiri IM Kool UU at al. Time scale performance of regidenticen testing for
414 /15	50.	Advise with Z, Alliudi 1 IVI, Kaai Fin, et al. Thile scale performance of rapid allugen lesting for SARS CoV 2: Evaluation of 10 rapid antigon assays. <i>LMad Viral</i> Dec 2021;02(12):6512,6512
41J /16		doi:10.1002/imy.27186
410		u01.10.1002/j111.2/100

417	31.	Chu VT, Schwartz NG, Donnelly MAP, et al. Comparison of Home Antigen Testing With RT-
418		PCR and Viral Culture During the Course of SARS-CoV-2 Infection. JAMA Internal Medicine.
419		2022;182(7):701-709. doi:10.1001/jamainternmed.2022.1827
420	32.	Brihn A, Chang J, K OY, et al. Diagnostic Performance of an Antigen Test with RT-PCR for the
421		Detection of SARS-CoV-2 in a Hospital Setting - Los Angeles County, California, June-August
422		2020. MMWR Morb Mortal Wkly Rep. May 14 2021;70(19):702-706.
423		doi:10.15585/mmwr.mm7019a3
424	33.	Centers for Disease Control and Prevention. Considerations for SARS-CoV-2 Antigen Testing for
425		Healthcare Providers Testing Individuals in the Community. September 27, 2023. Accessed
426		September 27, 2023. <u>https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-</u>
427		<u>guidelines.html</u>
428	34.	Killingley B, Mann AJ, Kalinova M, et al. Safety, tolerability and viral kinetics during SARS-
429		CoV-2 human challenge in young adults. <i>Nat Med.</i> May 2022;28(5):1031-1041.
430		doi:10.1038/s41591-022-01780-9
431	35.	Parvu V, Gary DS, Mann J, et al. Factors that Influence the Reported Sensitivity of Rapid
432		Antigen Testing for SARS-CoV-2. Original Research. Frontiers in Microbiology. 2021-October-
433		05 2021;12doi:10.3389/fmicb.2021.714242
434	36.	Smith RL, Gibson LL, Martinez PP, et al. Longitudinal Assessment of Diagnostic Test
435		Performance Over the Course of Acute SARS-CoV-2 Infection. J Infect Dis. Sep 17
436		2021;224(6):976-982. doi:10.1093/infdis/jiab337
437	37.	Public Health England. Understanding cycle threshold (Ct) in SARS-CoV-2 RT-PCR. November
438		8, 2023. Accessed November 8, 2023.
439		https://assets.publishing.service.gov.uk/media/5f85c/2/d3bf/f633cfcbd1f/Understanding_Cycle_
440	•	<u>Threshold_Ct_in_SARS-CoV-2_RT-PCRpdf</u>
441	38.	Jaafar R, Aherfi S, Wurtz N, et al. Correlation Between 3/90 Quantitative Polymerase Chain
442		Reaction-Positives Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory
443		Syndrome Coronavirus 2 Isolates. <i>Clin Infect Dis.</i> Jun 1 2021;72(11):e921.
444	20	doi:10.1093/cid/ciaa1491
445	39.	Madewell ZJ, Yang Y, Longini IM, Halloran ME, Vespignani A, Dean NE. Rapid review and
440		meta-analysis of serial intervals for SARS-Cov-2 Delta and Omicron variants. BMC Injectious
447 770	40	Diseases. 2025/00/20 2025;25(1):429. doi:10.1180/s128/9-025-0840/-5
448	40.	Madewell ZJ, Yang Y, Longini IM, Jr., Halloran ME, Dean NE. Household Secondary Allack
449		Mate analysis IAMA Netw Onen April 2022;5(4):5220217
450 451		dei 10. 1001/jemanetworkonen 2022.0217
451 152	41	Wu V. Kong L. Guo Z. Liu I. Liu M. Liong W. Insubation Deriod of COVID 10 Caused by
4JZ 152	41.	Unique SAPS CoV 2 Straine: A Systematic Pariou and Mate analysis IAMA Natural Open
455		2022:5(8):e2228008 e2228008 doi:10.1001/jamanetworkopen.2022.28008
434 155	12	Pubach O Meyer B. Eckerle I. SARS CoV 2 viral load and shedding kinetics. Nature Reviews
455	42.	Miarchiology 2022;21(2):147-161
450	13	Vang V. Guo I. Vuan I. et al. Viral and antibody dynamics of acute infection with SARS CoV 2
457	45.	omicron variant (B 1 1 529): a prospective cohort study from Shenzhen China Lancet Microbe
450 159		$\Delta_{110} = 2023 \cdot A(8) \cdot e^{632} \cdot e^{641} \cdot d_{0} \cdot 10 = 1016 / 2666 \cdot 5247 / 23)00139 \cdot 8$
460	11	Kim IM Kim D Lee NL et al. Increased viral load in patients infected with severe acute
461	44.	respiratory syndrome coronavirus 2 Omicron variant in the Republic of Korea. Osong Public
462		Health Res Perspect Aug 2023:14(4):272-278 doi:10.24171/j.phrp.2023.0024
463	45	Granerud BK Lleland T Lind A et al Omicron Variant Generates a Higher and More Sustained
464	10.	Viral Load in Nasonharynx and Saliya Than the Delta Variant of SARS-CoV-2 Viruses Oct 31
465		2022:14(11)doi:10.3390/v14112420
466	46.	Rao A. Westbrook A. Bassit L. et al. Sensitivity of Rapid Antigen Tests Against SARS-CoV-2
467		Omicron and Delta Variants. <i>medRxiv</i> . Feb 10 2023;doi:10.1101/2023.02.09.23285583

- 468 47. Soni A, Herbert C, Filippaios A, et al. Comparison of Rapid Antigen Tests' Performance Between 469 Delta and Omicron Variants of SARS-CoV-2 : A Secondary Analysis From a Serial Home Self-470 testing Study. Ann Intern Med. Dec 2022;175(12):1685-1692. doi:10.7326/m22-0760 471 48. Murakami M, Sato H, Irie T, et al. Sensitivity of rapid antigen tests for COVID-19 during the 472 Omicron variant outbreak among players and staff members of the Japan Professional Football 473 League and clubs: a retrospective observational study. BMJ Open. Jan 30 2023;13(1):e067591. 474 doi:10.1136/bmjopen-2022-067591 475 49. Centers for Disease Control and Prevention. Overview of Testing for SARS-CoV-2, the virus that causes COVID-19. September 27, 2023. Accessed September 27, 2023. 476 477 https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html 478 50. Stohr JJJM, Zwart VF, Goderski G, et al. Self-testing for the detection of SARS-CoV-2 infection 479 with rapid antigen tests for people with suspected COVID-19 in the community. Clinical 480 Microbiology and Infection. 2022/05/01/2022;28(5):695-700. 481 doi:https://doi.org/10.1016/j.cmi.2021.07.039 482 51. Wölfl-Duchek M, Bergmann F, Jorda A, et al. Sensitivity and specificity of SARS-CoV-2 rapid 483 antigen detection tests using oral, anterior nasal, and nasopharyngeal swabs: a diagnostic 484 accuracy study. *Microbiology spectrum*. 2022;10(1):e02029-21. 485 52. Centers for Disease Control and Prevention. Variant Proportions. October 2, 2023. Accessed 486 October 2, 2023. https://covid.cdc.gov/covid-data-tracker/
- 487

488 Figure Titles and Legends

- 489 Figure 1. Sensitivity and specificity of BinaxNOW Antigen test compared to RT-PCR by days post
- 490 onset of symptoms (N = 1181 paired tests from 921 participants with 0 to 16 days post onset). The
- 491 blue line represents a cubic spline and grey bands indicate 95% confidence intervals of the model fit.
- 492 Vertical bars are 95% confidence intervals of BinaxNOW sensitivity and specificity for each days-post-
- 493 onset subgroup. There were 1181 tests of both BinaxNOW and RT-PCR.
- 494 Figure 2. Sensitivity of BinaxNOW Antigen test compared to RT-PCR for initial tests and repeated
- 495 tests 7–14 days later by symptom status for the initial and repeated tests (N = 368 paired tests from
- 496 **184 participants).** Additional diagnostic accuracy measures are shown in S2 Table. There were 368 tests
- 497 of both BinaxNOW and RT-PCR.

	Overall	COPA	SEDSS
	N = 1207	N = 943	N = 264
Age in years (median [IQR])	36 [16, 49]	36 [16, 47]	36 [19, 58]
Age group in years (%) (N = 1207)		• • •	
0–10	149 (12.3)	96 (10.2)	53 (20.1)
11–20	222 (18.4)	208 (22.1)	14 (5.3)
21–30	146 (12.1)	102 (10.8)	44 (16.7)
31–40	180 (14.9)	142 (15.1)	38 (14.4)
41–50	263 (21.8)	237 (25.1)	26 (9.8)
51+	247 (20.5)	158 (16.8)	89 (33.7)
Sex (%) (N = 1206)			
Female	692 (57.4)	552 (58.6)	140 (53.0)
Male	514 (42.6)	390 (41.4)	124 (47.0)
Hispanic/Latino (%) (N = 1171)			
Yes	1168 (99.7)	912 (100.0)	256 (98.8)
No	3 (0.3)	0 (0)	3 (1.2)
Ethnicity (%) (N = 1170)			
Puerto Rican	1152 (98.5)	900 (98.8)	252 (97.3)
Other	18 (1.5)	11 (1.2)	7 (2.7)
Race (%) (N = 1118)			
Black	122 (10.9)	93 (10.4)	29 (12.9)
Mixed	101 (9.0)	85 (9.5)	16 (7.1)
White	849 (75.9)	685 (76.7)	164 (72.9)
Other	46 (4.1)	30 (3.4)	16 (7.1)
Chronic medical conditions (%) (N = 1205)			
Yes	679 (56.3)	531 (56.3)	148 (56.5)
No	526 (43.7)	412 (43.7)	114 (43.5)
COVID-19 vaccine doses recorded on final visit (%) (N = 1063)			
0	310 (29.2)	46 (5.8)	264 (100)
1	14 (1.5)	14 (1.8)	0 (0)
2	290 (30.5)	290 (36.3)	0 (0)
3	435 (45.7)	435 (54.4)	0 (0)
4	14 (1.5)	14 (1.8)	0 (0)
Symptomatic during study (%) (N = 1203)	. ,	. ,	
Yes	1030 (85.6)	770 (81.7)	260 (100)
No	173 (14.4)	173 (18.3)	0 (0)
Days from symptom onset to testing (median [IQR]) (N = 923)	4 [2, 6]	4 [3, 7]	2 [1, 4]
Number of RT-PCR/BinaxNOW tests (%) (N = 1207)			
1	733 (60 7)	527 (55.9)	206 (78.0)
2	318 (26.3)	260 (27.6)	$58(220)^{a}$
3	94 (7.8)	94 (10.0)	0 (0 0)
≥4	62 (5.1)	62 (6.6) ^b	0 (0.0)

Table 1. Demographic characteristics of participants from COPA and SEDSS, 20)20-
2023.	

IQR: interquartile range; COPA: Communities Organized to Prevent Arboviruses; SEDSS: Sentinel Enhanced Dengue Surveillance System; RT-PCR: reverse transcription polymerase chain reaction. ^a All repeat testing for SEDSS participants was performed on the same day with one swab collected by a healthcare provider and another self-collected swab. ^b For repeated tests among COPA participants, tests separated by ≥90 days were considered as part of

^b For repeated tests among COPA participants, tests separated by ≥90 days were considered as part of separate illness episodes, and tests within 7–14 days of each other were considered part of the same illness episode. COPA participant tests performed between 15–89 days of another test were excluded from the analysis.

	True	True	False	False			Positive	Negative	McNemar's
	Positive,	Negative,	Positive,	Negative,	Sensitivity	Specificity	Predictive Value	Predictive Value	Chi Square
	n (%)	n (%)	n (%)	n (%)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	<i>P</i> value [⊳]
Overall	391 (25.6)	1052 (68.8)	13 (0.8)	74 (4.8)	84.1 (80.4, 87.3)	98.8 (97.9, 99.3)	96.8 (94.6, 98.3)	93.4 (91.8, 94.8)	<0.001
Days post onset ^c									
0	15 (20.0)	55 (73.3)	0 (0)	5 (6.7)	75.0 (50.9, 91.3)	100 (93.5, 100)	100 (78.2, 100)	91.7 (81.6, 97.2)	0.074
1–3	129 (26.9)	337 (70.2)	3 (0.6)	11 (2.3)	92.1 (86.4, 96.0)	99.1 (97.4, 99.8)	97.7 (93.5, 99.5)	96.8 (94.4, 98.4)	0.061
4–6	145 (40.4)	201 (56.0)	4 (1.1)	9 (2.5)	94.2 (89.2, 97.3)	98.0 (95.1, 99.5)	97.3 (93.3, 99.3)	95.7 (92.0, 98.0)	0.267
≥7	85 (30.6)	154 (55.4)	3 (1.1)	36 (12.9)	70.2 (61.3, 78.2)	98.1 (94.5, 99.6)	96.6 (90.4, 99.3)	81.1 (74.7, 86.4)	<0.001
Symptomatology ^d									
Asymptomatic	37 (11.9)	252 (81.3)	3 (1.0)	18 (5.8)	67.3 (53.3, 79.3)	98.8 (96.6, 99.8)	92.5 (79.6, 98.4)	93.3 (89.7, 96.0)	0.002
≥1 symptom	353 (29.0)	797 (65.5)	10 (0.8)	56 (4.6)	86.3 (82.6, 89.5)	98.8 (97.7, 99.4)	97.2 (95.0, 98.7)	93.4 (91.6, 95.0)	<0.001
1–3 symptoms	266 (30.5)	556 (63.8)	9 (1.0)	41 (4.7)	86.6 (82.3, 90.2)	98.4 (97.0, 99.3)	96.7 (93.9, 98.5)	93.1 (90.8, 95.0)	< 0.001
4–6 symptoms	24 (19.4)	92 (74.2)	0 (0)	8 (6.5)	75.0 (56.6, 88.5)	100 (96.1, 100)	100 (85.8, 100)	92.0 (84.8, 96.5)	0.013
7–9 symptoms	20 (19.4)	80 (77.7)	0 (0)	3 (2.9)	87.0 (66.4, 97.2)	100 (95.5, 100)	100 (83.2, 100)	96.4 (89.8, 99.2)	0.248
≥10 symptoms	43 (36.8)	69 (59.0)	1 (0.9)	4 (3.4)	91.5 (79.6, 97.6)	98.6 (92.3, 100)	97.7 (88.0, 99.9)	94.5 (86.6, 98.5)	0.371
Collection strategy									
Self, SEDSS	46 (34.3)	80 (59.7)	0 (0)	8 (6.0)	85.2 (72.9, 93.4)	100 (95.5, 100)	100 (92.3, 100)	90.9 (82.9, 96.0)	0.013
Staff, SEDSS	23 (12.2)	159 (84.6)	0 (0)	6 (3.2)	79.3 (60.3, 92.0)	100 (97.7, 100)	100 (85.2, 100)	96.4 (92.3, 98.7)	0.041
Self + Staff, SEDSS	69 (21.4)	239 (74.2)	0 (0)	14 (4.3)	83.1 (73.3, 90.5)	100 (98.5, 100)	100 (94.8, 100)	94.5 (90.9, 96.9)	0.001
Staff, COPA	322 (26.7)	813 (67.3)	13 (1.1)	60 (5.0)	84.3 (80.2, 87.8)	98.4 (97.3, 99.2)	96.1 (93.5, 97.9)	93.1 (91.2, 94.7)	< 0.001
Staff, SEDSS + COPA	345 (24.7)	972 (69.6)	13 (0.9)	66 (4.7)	83.9 (80.0, 87.4)	98.7 (97.8, 99.3)	96.4 (93.9, 98.1)	93.6 (92.0, 95.0)	<0.001
Repeated tests ^e									
Initial test	105 (57.1)	72 (39.1)	3 (1.6)	4 (2.2)	96.3 (90.9, 99.0)	96.0 (88.8, 99.2)	97.2 (92.1, 99.4)	94.7 (87.1, 98.5)	1
Repeated test 7–14									-0.001
days after initial test	29 (15.8)	122 (66.3)	3 (1.6)	30 (16.3)	49.2 (35.9, 62.5)	97.6 (93.1, 99.5)	90.6 (75.0, 98.0)	80.3 (73.0, 86.3)	<0.001
Number of vaccine									
doses ^r									
Unvaccinated	99 (19.9)	378 (75.9)	0 (0)	21 (4.2)	82.5 (74.5, 88.8)	100 (99.0, 100)	100 (96.3, 100)	94.7 (92.1, 96.7)	<0.001
1 dose	7 (16.3)	33 (76.7)	1 (2.3)	2 (4.7)	77.8 (40.0, 97.2)	97.1 (84.7, 99.9)	87.5 (47.3, 99.7)	94.3 (80.8, 99.3)	1
2 doses	100 (22.9)	310 (71.1)	2 (0.5)	24 (5.5)	80.6 (72.6, 87.2)	99.4 (97.7, 99.9)	98.0 (93.1, 99.8)	92.8 (89.5, 95.3)	<0.001
3 doses	144 (38.6)	201 (53.9)	8 (2.1)	20 (5.4)	87.8 (81.8, 92.4)	96.2 (92.6, 98.3)	94.7 (89.9, 97.7)	91.0 (86.4, 94.4)	0.038
4 doses	2 (22.2)	6 (66.7)	1 (11.1)	0 (0)	100 (15.8, 100)	85.7 (42.1, 99.6)	66.7 (9.4, 99.2)	100 (54.1, 100)	1
Predominant SARS-CoV-	2 variant								
Pre-Delta	80 (16.7)	379 (79.1)	0 (0)	20 (4.2)	80.0 (70.8, 87.3)	100 (99.0, 100)	100 (95.5, 100)	95.0 (92.4, 96.9)	<0.001
Delta	7 (4.2)	156 (94.0)	0 (0)	3 (1.8)	70.0 (34.8, 93.3)	100 (97.7, 100)	100 (59.0, 100)	98.1 (94.6, 99.6)	0.248
Omicron	304 (34.4)	517 (58.4)	13 (1.5)	51 (5.8)	85.6 (81.5, 89.1)	97.5 (95.8, 98.7)	95.9 (93.1, 97.8)	91.0 (88.4, 93.2)	< 0.001

Table 2. Comparison of BinaxNOW and RT-PCR (N = 1530 paired^a tests from 1207 participants unless stated otherwise).

RT-PCR: reverse transcription polymerase chain reaction; CI: confidence interval

^a There were 1530 tests of both BinaxNOW and RT-PCR.

^b We used McNemar's test to evaluate differences in proportions of discordant pairs (i.e., the differences between false positives and false negatives) between BinaxNOW and the reference standard, RT-PCR. It helps determine if one test is more likely to produce false positives or false negatives compared to the other.

^c N = 1192 tests from 923 participants—284 participants were missing symptom onset dates.

^d N = 1526 tests from 1203 participants—4 participants were missing symptom data. Symptoms included tiredness, cough, loss of smell, dyspnea, myalgia, throat pain, chest pain, nausea/vomiting, diarrhea, abdominal pain, nasal congestion, chills, conjunctivitis, skin changes, rash, arthralgia, eye pain, bleeding, irritability, and calf pain.

^e N = 368 tests from 184 participants. Restricted to participants who had repeated tests.

^f N = 1359 tests from 1063 participants—144 participants were missing vaccination data.

	Positive likelihood	Negative likelihood ratio	Correctly classified	Apparent positivity	True positivity	Number needed to diagnose (95%	AUC-
Overall	68 89 (40 07 118 41)		0 943 (0 930 0 954)				0.914
Days post onset ^b	00.03 (40.07, 110.41)	0.10 (0.13, 0.20)	0.343 (0.330, 0.334)	0.204 (0.242, 0.207)	0.304 (0.201, 0.320)	1.2 (1.2, 1.3)	0.514
0	Inf	0.25 (0.12, 0.53)	0.933 (0.851, 0.978)	0.200 (0.116, 0.308)	0.267 (0.171, 0.381)	1.3 (1.1, 2.3)	0.875
1–3	104.43 (33.81, 322.51)	0.08 (0.04, 0.14)	0.971 (0.952, 0.984)	0.275 (0.236, 0.317)	0.292 (0.251, 0.335)	1.1 (1.0, 1.2)	0.956
4–6	48.25 (18.27, 127.44)	0.06 (0.03, 0.11)	0.964 (0.939, 0.981)	0.415 (0.364, 0.468)	0.429 (0.377, 0.482)	1.1 (1.0, 1.2)	0.961
≥7	36.76 (11.91, 113.43)	0.30 (0.23, 0.40)	0.860 (0.813, 0.898)	0.317 (0.262, 0.375)	0.435 (0.376, 0.496)	1.5 (1.3, 1.8)	0.842
Symptomatology ^c			· · · · · ·	,	· · · /		
Asymptomatic	57.18 (18.29, 178.78)	0.33 (0.23, 0.48)	0.932 (0.898, 0.958)	0.129 (0.094, 0.172)	0.177 (0.137, 0.225)	1.5 (1.3, 2.0)	0.830
≥1 symptom	69.65 (37.58, 129.11)	0.14 (0.11, 0.18)	0.946 (0.931, 0.958)	0.299 (0.273, 0.325)	0.336 (0.310, 0.364)	1.2 (1.1, 1.2)	0.925
1–3 symptoms	54.39 (28.41, 104.15)	0.14 (0.10, 0.18)	0.943 (0.925, 0.957)	0.315 (0.285, 0.347)	0.352 (0.320, 0.385)	1.2 (1.1, 1.3)	0.925
4–6 symptoms	Inf	0.25 (0.14, 0.46)	0.935 (0.877, 0.972)	0.194 (0.128, 0.274)	0.258 (0.184, 0.344)	1.3 (1.1, 1.9)	0.875
7–9 symptoms	Inf	0.13 (0.05, 0.37)	0.971 (0.917, 0.994)	0.194 (0.123, 0.284)	0.223 (0.147, 0.316)	1.2 (1.0, 1.6)	0.935
≥10 symptoms	64.04 (9.13, 449.18)	0.09 (0.03, 0.22)	0.957 (0.903, 0.986)	0.376 (0.288, 0.470)	0.402 (0.312, 0.496)	1.1 (1.0, 1.4)	0.950
Collection strategy							
Self, SEDSS	Inf	0.15 (0.08, 0.28)	0.940 (0.886, 0.974)	0.343 (0.263, 0.430)	0.403 (0.319, 0.491)	1.2 (1.1, 1.5)	0.926
Staff, SEDSS	Inf	0.21 (0.10, 0.42)	0.968 (0.932, 0.988)	0.122 (0.079, 0.178)	0.154 (0.106, 0.214)	1.3 (1.1, 1.7)	0.897
Self + Staff, SEDSS	Inf	0.17 (0.10, 0.27)	0.957 (0.928, 0.976)	0.214 (0.171, 0.263)	0.258 (0.211, 0.309)	1.2 (1.1, 1.4)	0.916
Staff, COPA	53.56 (31.18, 92.00)	0.16 (0.13, 0.20)	0.940 (0.925, 0.952)	0.277 (0.252, 0.303)	0.316 (0.290, 0.343)	1.2 (1.2, 1.3)	0.914
Staff, SEDSS + COPA	63.60 (37.00, 109.32)	0.16 (0.13, 0.20)	0.943 (0.930, 0.955)	0.256 (0.234, 0.280)	0.294 (0.271, 0.319)	1.2 (1.2, 1.3)	0.913
Repeated tests ^d							
Initial test	24.08 (7.94, 73.03)	0.04 (0.01, 0.10)	0.962 (0.923, 0.985)	0.587 (0.512, 0.659)	0.592 (0.518, 0.664)	1.1 (1.0, 1.3)	0.961
Repeated test 7–14							
days after initial test	20.48 (6.50, 64.53)	0.52 (0.40, 0.67)	0.821 (0.757, 0.873)	0.174 (0.122, 0.237)	0.321 (0.254, 0.393)	2.1 (1.6, 3.4)	0.734
Number of vaccine doses	S ^e						
Unvaccinated	Inf	0.18 (0.12, 0.26)	0.958 (0.936, 0.974)	0.199 (0.165, 0.237)	0.241 (0.204, 0.281)	1.2 (1.1, 1.4)	0.913
1 dose	26.44 (3.72, 188.16)	0.23 (0.07, 0.78)	0.930 (0.809, 0.985)	0.186 (0.084, 0.334)	0.209 (0.100, 0.360)	1.3 (1.0, 4.1)	0.874
2 doses	125.81 (31.52, 502.14)	0.19 (0.14, 0.28)	0.940 (0.914, 0.961)	0.234 (0.195, 0.277)	0.284 (0.242, 0.329)	1.2 (1.1, 1.4)	0.900
3 doses	22.94 (11.60, 45.37)	0.13 (0.08, 0.19)	0.925 (0.893, 0.950)	0.408 (0.357, 0.459)	0.440 (0.389, 0.492)	1.2 (1.1, 1.3)	0.920
4 doses	7.00 (1.14, 42.97)	0.00 (0.00, 0.00)	0.889 (0.518, 0.997)	0.333 (0.075, 0.701)	0.222 (0.028, 0.600)	1.2 (-2.4, 1.0)	0.929
Predominant SARS-CoV-	2 variant						
Pre-Delta	Inf	0.20 (0.14, 0.30)	0.958 (0.936, 0.974)	0.167 (0.135, 0.203)	0.209 (0.173, 0.248)	1.2 (1.1, 1.4)	0.900
Delta	Inf	0.30 (0.12, 0.77)	0.982 (0.948, 0.996)	0.042 (0.017, 0.085)	0.060 (0.029, 0.108)	1.4 (1.1, 3.1)	0.850
Omicron	34.91 (20.37, 59.82)	0.15 (0.11, 0.19)	0.928 (0.909, 0.944)	0.358 (0.327, 0.391)	0.401 (0.369, 0.434)	1.2 (1.1, 1.3)	0.916

Table 3. Performance of BinaxNOW compared to RT-PCR (N = 1530 paired^a tests from 1207 participants unless stated otherwise).

RT-PCR: reverse transcription polymerase chain reaction; CI: confidence interval; AUC-ROC: Area Under the Receiver Operating Characteristic Curve

^a There were 1530 tests of both BinaxNOW and RT-PCR.

 b N = 1192 tests from 923 participants—284 participants were missing symptom onset dates.

^c N = 1526 tests from 1203 participants—4 participants were missing symptom data. Symptoms included tiredness, cough, loss of smell, dyspnea, myalgia, throat pain, chest pain, nausea/vomiting, diarrhea, abdominal pain, nasal congestion, chills, conjunctivitis, skin changes, rash, arthralgia, eye pain, bleeding, irritability, and calf pain.

^d N = 368 tests from 184 participants. Restricted to participants who had repeated tests.

^e N = 1359 tests from 1063 participants—144 participants were missing vaccination data.

501

Table 4. Sensitivity of BinaxNOW by Ct values of RT-PCRtests (N = 464 paired^a tests from 435 participants).

Ct value	Positive PCR tests N	Positive BinaxNOW tests N (%)	Negative BinaxNOW tests N (%)
≤25	198	197 (99.5)	1 (0.5)
26–30	121	113 (93.4)	8 (6.6)
31–35	101	72 (71.3)	29 (28.7)
36–40	44	8 (18.2)	36 (81.8)

RT-PCR: reverse transcription polymerase chain reaction. ^a This table includes positive RT-PCR tests and corresponding BinaxNOW test results. Of 465 total positive RT-PCR tests, 1 was missing a Ct value, therefore the sample size includes 464 tests of both BinaxNOW and RT-PCR.







